Year 2009 | From May to July, in response to the H1N1 influenza epidemic, Ai Baojun, Deputy Mayor of Shanghai, Wang Zxiong, Deputy Director of the Safety Supervision Department of the State Food and Drug Administration, and Director of the Drug Certification Management Center of the State Food and Drug Administration Zhang Aiping, Lin Yulong, Deputy Inspector of the Operation Inspection Coordination Bureau of the Ministry of Industry and Information Technology, Jing Xiaobo, Director of the Emergency Coordination Division, Li Hong, Director of the Pharmaceutical Division of the Consumer Goods Industry Department, and other relevant leaders led the team to investigate and inspect the company Ost Production and quality control of Wei capsule. |
Year 2008 | From May 19 to 23, 3D passed the on-site inspection of FDA smoothly. |
In 2007 | In 2007, "Shanghai High-tech Enterprise" passed the review. On April 23, it passed the FDA inspection for the first time with zero defects. This is 3D. Since it was accepted by the FDA on-site inspection in September 1990, this has provided a channel for 3D company s API products to continue to enter the U.S. market. Entering the US market has won more opportunities and development space. |
year 2006 | On April 25th, the "Anti-Avian Influenza Drug Development Team" of Shanghai 3D Drug Research Center won the "Shanghai May 1 Labor Medal". Oseltamivir Phosphate and Olfi Capsule won the "2005 Shanghai Municipal Key Industrialization Technology Industry-University-Research Joint Project". The first batch of oseltamivir phosphate capsules put into production, with an output of 100,000 tablets and 50,000 boxes, officially entered the circulation field on November 24, 2006. In 2006, by virtue of independent innovation capabilities and core technological advantages, and its role in sustainable development in the fields of resource conservation and comprehensive utilization, environmental protection, etc., it was awarded the Shanghai Economic Commission, Shanghai National Taxation Bureau, and Shanghai Finance Bureau of Shanghai, Shanghai Local Taxation Bureau and Shanghai Customs jointly issued the "Shanghai Certified Enterprise Technology Center" bronze medal. |
In 2005 | In May, Sanwei won the production approval of Docetaxel and obtained China GMP certification. In December, 3D successfully developed the oseltamivir phosphate raw materials and preparations in China, and obtained the final production authorization. In December, 3D obtained the GMP re-certification certificate from the National SFDA for the solid preparation workshop. |
year 2004 | In April, the company acquired Hualian Sales Company to establish 3D Pharmaceutical Sales Co., Ltd., and passed GSP certification in late June. In May, the subsidiary Sanwei Changjiang Biochemical Plant passed GMP certification inspection. In May, the company's third-generation cephalosporin new product cefpodoxime ester (brand name Wei Jiexin) was put into production in the second drug substance manufacturing department. In August, the company's new product, rosiglitazone hydrochloride, was invalidated, and it passed the clinical research and acceptance in November. |
Year 2003 | In September, the company's cefpodoxime APIs and tablets were successfully launched. In September, 3D joined the Pharmaceutical Group, one of the core strategic sections of the Shanghai Pharmaceutical Group. |
year 2002 | The company's Weishaxin products won the "Shanghai Second Prize for Outstanding New Products". The company won the title of "National Excellent Double Investment Enterprise". |
2001 | The company Sanweikang product intermediate obtained the process invention patent. |
Year 2000 | In June, the strategic cooperation relationship with the French Pierre Faber company for product license production and sales was determined. In August, it cooperated with Swiss Hoffmann-Roche to implement a vitamin C refining technology transformation project. |
After 1999 | The company has been awarded the Shanghai Civilization Construction Commendation Unit and Shanghai Civilization Unit for many times. |
Year 1999 | Obtained GMP certificate of Chinese medicines (No. A0088). |
1998 | The pharmaceutical preparation obtained the Chinese medicine GMP certificate, and passed the SDA exemption certification in 2000 (No. B0342). |
year 1996 | Fluconazole won the second prize of Shanghai Science and Technology Progress Award and the first prize of outstanding new product. On August 28, Mr. Luo Shiqian, the current Secretary of the Organization Committee of the Shanghai Municipal Party Committee, visited the three-dimensionally. Co-founded 3D Drug Research Center with Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences. |
the year 1995 | In 1995, the company obtained the qualification certification of Shanghai Enterprise Technology Center. As one of the "hundreds of pilot enterprises of modern enterprise system in the country", the company fully implements the pilot work of modern enterprise system. On April 16th, State Councilor Li Tieying came to inspect in three dimensions. In May, it won the honor of "Best Industrial Enterprise Image Unit in Shanghai". On May 4th, Mr. Huang Ju, Secretary of the Shanghai Municipal Party Committee and Mr. Jiang Yiren, Deputy Mayor, inspected in three dimensions. On September 6th, Shanghai Givaudan Roya Co., Ltd. was established as a joint venture with Swiss Hoffmann-Roche. On November 23rd, Roche 3D (Shanghai) Vitamin Co., Ltd. was established through a joint venture with Hoffmann-Roche of Switzerland. After that, the company merged with two other Roche joint ventures, and the shares were transferred to Shanghai Pharmaceutical Group Co., Ltd. On November 25th, Mr. Zheng Xiaozheng, the director of the State Pharmaceutical Administration, visited the company. In December, 3D Pharmaceutical, an open-type, outward-oriented and comprehensive joint venture, was established and was packaged for listing on the Hong Kong Stock Exchange with four companies including Shanghai Jahwa Co. Ltd. |
year 1994 | Ciprofloxacin lactate won the third prize of Shanghai Excellent New Product. Established Shanghai Roche Pharmaceutical Co., Ltd., the first Sino-foreign joint venture in 3D, with Swiss Hoffmann-Roche. |
1993 | The company obtained the qualification certificate of Shanghai High-tech Enterprise. |
1992 | Bibenazole was awarded the third prize of Shanghai Science and Technology Progress Award. In December, the company obtained the right to self-support import and export business, and the API products have been sold to more than 50 countries and regions including Europe and the United States. |
year 1991 | The company was awarded the title of Shanghai Greening Advanced Unit. Ciprofloxacin hydrochloride won the first prize of Shanghai Excellent New Product. In 1993, the product won the first prize of Shanghai Science and Technology Progress Award. |
1990 | Many of the company's products have applied for FDA certification and EU registration. |
in 1989 | Established 3D's first Sino-foreign cooperative enterprise with Shanghai Schering-Plough Corporation, Shanghai-3D Baoling Pharmaceutical Factory |
1985 | The largest soft technology export project since the founding of the People's Republic of China-Vitamin C two-step fermentation technology was transferred to Swiss Hoffmann-Roche. |
1983 | The company successfully built a biological oxidation treatment station with a daily processing capacity of 6,000 tons of wastewater, which improved the surrounding environment. |
1982 | Vitamin B1 was successfully put into operation in the company. |
1981 | The company successfully put into production and built a VE production workshop, realizing the situation that sulfa drugs and vitamins are developed with equal emphasis. |
1974 | The company took the lead in realizing the medium-sized experiment of the new technology of vitamin C two-step fermentation in the country, and successfully carried out the production of 400 tons of new technology in the following year. |
1959 | The company began to invest in the establishment of a vitamin C product production line and officially produced VC products. |
1958 | Sanwei Pharmaceutical's predecessor, Shanghai No. 2 Pharmaceutical Factory, was established. It is the only new synthetic pharmaceutical factory in Shanghai after the founding of New China. |
